Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nkarta to Participate in Evercore Healthcare Conference GlobeNewswire - Tue Dec 2, 6:09AM CST

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 1.8000 (-2.17%)
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights  GlobeNewswire - Mon Nov 10, 3:01PM CST

Enrollment now underway in second dose-escalation cohort  Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide...

NKTX : 1.8000 (-2.17%)
Nkarta to Participate in November Investor Conferences GlobeNewswire - Thu Oct 30, 12:14PM CDT

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

NKTX : 1.8000 (-2.17%)
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting GlobeNewswire - Wed Oct 22, 9:07AM CDT

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 1.8000 (-2.17%)
Nkarta to Participate in a September Investor Conference GlobeNewswire - Tue Sep 2, 7:01AM CDT

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

NKTX : 1.8000 (-2.17%)
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights GlobeNewswire - Tue Aug 12, 3:01PM CDT

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected...

NKTX : 1.8000 (-2.17%)
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series GlobeNewswire - Wed Jul 23, 7:01AM CDT

SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

NKTX : 1.8000 (-2.17%)
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus GlobeNewswire - Fri Jun 6, 7:52AM CDT

NKTX : 1.8000 (-2.17%)
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights GlobeNewswire - Wed May 14, 3:01PM CDT

NKTX : 1.8000 (-2.17%)
Nkarta to Participate in an April Investor Conference GlobeNewswire - Tue Apr 1, 7:01AM CDT

NKTX : 1.8000 (-2.17%)

Barchart Exclusives

Rate Decision, Tech Earnings and Other Key Things to Watch this Week Barchart - Sun Dec 7, 12:00PM CST
Markets face the year's final major policy week as the Federal Reserve's December meeting Wednesday afternoon will determine whether the central bank delivers another rate cut or pauses its easing cycle amid mixed economic signals and persistent inflation concerns. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot